Chronic Fatigue Syndrome Trial, Recruiting NCT07154199 Sponsor: Xuanwu Hospital, Beijing Condition: Chronic Fatigue Syndrome
Back to Chronic Fatigue Syndrome

Chronic Fatigue Syndrome Trial, Recruiting

NCT07154199
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have previously had COVID-19, confirmed by either a PCR test or a rapid antigen test
  • You are still experiencing "brain fog" symptoms (such as difficulty thinking, concentrating, or remembering) at least 4 weeks after recovering from your initial COVID-19 illness

Who may not be able to join:

  • You had any problems with memory, thinking, or other neurological symptoms before you got COVID-19
  • A brain MRI scan has shown significant abnormalities or structural problems in your brain
  • You developed serious brain or nervous system complications after your COVID-19 infection, such as delirium, a stroke, brain inflammation, or seizures/epilepsy (confirm with trial site)
  • You have been diagnosed with a condition that can affect memory or thinking, such as dementia, Alzheimer's disease, Parkinson's disease, schizophrenia, or have had a stroke

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yi Tang, MD., PhD, Xuanwu Hospital, Beijing

Phone: 00861083198673

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Xuanwu Hospital, Beijing
Registry
ClinicalTrials.gov
Start date
6 January 2023
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

false alarm rate change; accuracy change

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov